Líffræðifélag Íslands - biologia.is
Líffræðiráðstefnan 2025
Erindi/veggspjald / Talk/poster E5
Höfundar / Authors: Thelma Rakel Ottesen1, Vilhjálmur Svansson1, Sigurbjörg Þorsteinsdóttir1, Hans Grönlund2, Eliane Marti3, Sigríður Jónsdóttir1,4
Starfsvettvangur / Affiliations: 1Institute for Experimental Pathology, Biomedical Center, University of Iceland, Keldur, Reykjavik, Iceland. 2Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. 3Division of Neurological Sciences, Department of Clinical Research and Veterinary Public Health, Vetsuisse Faculty, University of Berne, Bern, Switzerland. 4Faculty of Medicine, U
Kynnir / Presenter: Thelma Rakel Ottesen
Background: Insect bite hypersensitivity (IBH) is an IgE-mediated skin allergy of horses caused by bites of Culicoides. IBH is not a problem in Iceland due to absence of the causative insects, but 30-60% of exported horses develop IBH. Vaccination of healthy horses with 9 major allergens in Alum/MPLA adjuvants failed to reduce the prevalence of IBH after export. Our aim was to compare the immune response of horses following vaccination with allergens in MPLA alone to MPLA combined to Alum. Methods: Horses were vaccinated 3 times with Culo8 and Culo9; 6 with the allergens in MPLA and 6 in Alum/MPLA. Allergen-specific IgG subclasses were measured by ELISA. IFNg, IL-10 and IL-4 were measured by bead-based multiplex assay after PBMC re-stimulation. Results: Similar levels of allergen-specific IgG1 and IgG4/7 were induced in both groups following vaccination. However, the level of IgG5 was significantly lower in the MPLA group. Accordingly, the ratio of IgG1 and IgG4/7 to IgG5 was significantly higher in MPLA group. Similar level of IFNg was measured in both groups, the MPLA group had slightly higher IL-10 and lower IL-4 as compared to the Alum/MPLA group, but the difference did not reach significance. Conclusions: MPLA as an adjuvant induced significantly lower IgG5, slightly less IL-4 and slightly more IL-10 indicating a regulatory immune response. Based on this MPLA could be used to induce an allergen-specific regulatory response sufficient for preventive allergy vaccination